[go: up one dir, main page]

AU2003239197A8 - Novel stable anti-cd22 antibodies - Google Patents

Novel stable anti-cd22 antibodies

Info

Publication number
AU2003239197A8
AU2003239197A8 AU2003239197A AU2003239197A AU2003239197A8 AU 2003239197 A8 AU2003239197 A8 AU 2003239197A8 AU 2003239197 A AU2003239197 A AU 2003239197A AU 2003239197 A AU2003239197 A AU 2003239197A AU 2003239197 A8 AU2003239197 A8 AU 2003239197A8
Authority
AU
Australia
Prior art keywords
antibodies
stable anti
novel stable
novel
stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003239197A
Other versions
AU2003239197A1 (en
Inventor
Michaela Arndt
Jurgen Krauss
Susanna Rybak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Government of the United States of America
Original Assignee
US Department of Health and Human Services
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Government of the United States of America filed Critical US Department of Health and Human Services
Publication of AU2003239197A8 publication Critical patent/AU2003239197A8/en
Publication of AU2003239197A1 publication Critical patent/AU2003239197A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2003239197A 2002-06-07 2003-06-09 Novel stable anti-cd22 antibodies Abandoned AU2003239197A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38730602P 2002-06-07 2002-06-07
US60/387,306 2002-06-07
PCT/US2003/018201 WO2003104425A2 (en) 2002-06-07 2003-06-09 Novel stable anti-cd22 antibodies

Publications (2)

Publication Number Publication Date
AU2003239197A8 true AU2003239197A8 (en) 2003-12-22
AU2003239197A1 AU2003239197A1 (en) 2003-12-22

Family

ID=29736288

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003239197A Abandoned AU2003239197A1 (en) 2002-06-07 2003-06-09 Novel stable anti-cd22 antibodies

Country Status (2)

Country Link
AU (1) AU2003239197A1 (en)
WO (1) WO2003104425A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2342929T3 (en) 2001-09-26 2010-07-19 The Government of the United States of America as represented by the Secretary of Health and Human ANTI-CD22 ANTIBODIES INCREASED BY THE LEUCEMIC CELLS THAT EXPRESS CD22.
JPWO2004087763A1 (en) * 2003-03-31 2006-07-27 中外製薬株式会社 Modified antibody against CD22 and use thereof
ES2558338T3 (en) 2005-03-25 2016-02-03 National Research Council Of Canada Method for isolation of soluble polypeptides
JP5620626B2 (en) 2005-03-31 2014-11-05 中外製薬株式会社 Polypeptide production method by association control
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
KR101360671B1 (en) 2005-06-10 2014-02-07 추가이 세이야쿠 가부시키가이샤 Pharmaceutical compositions containing sc(Fv)2
EP1908482B1 (en) 2005-06-10 2017-09-06 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
WO2014057118A1 (en) * 2012-10-12 2014-04-17 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
ES2881306T3 (en) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Method for the production of heteromultimers of polypeptides
JP7219005B2 (en) 2015-12-28 2023-02-07 中外製薬株式会社 Methods for Streamlining Purification of Fc Region-Containing Polypeptides
CN120535649A (en) 2018-08-30 2025-08-26 免疫生物公司 Single-chain chimeric polypeptides and uses thereof
CN112888445B (en) 2018-08-30 2025-06-10 免疫生物公司 Methods for treating age-related conditions
NZ772550A (en) 2018-08-30 2025-08-29 Immunitybio Inc Multi-chain chimeric polypeptides and uses thereof
KR20210152472A (en) * 2019-03-11 2021-12-15 메모리얼 슬로안 케터링 캔서 센터 CD22 antibody and methods of using the same
KR20220035394A (en) 2019-06-21 2022-03-22 에이치씨더블유 바이올로직스, 인크. Multi-chain chimeric polypeptides and uses thereof
AU2021220870A1 (en) 2020-02-11 2022-08-04 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
WO2021163298A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
KR20220140535A (en) 2020-02-11 2022-10-18 에이치씨더블유 바이올로직스, 인크. Chromatographic resins and uses thereof
CN115836087A (en) 2020-04-29 2023-03-21 Hcw生物科技公司 Anti-CD26 protein and use thereof
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
KR20230031280A (en) 2020-06-01 2023-03-07 에이치씨더블유 바이올로직스, 인크. Methods of treating age-related disorders
JP2025508939A (en) 2022-03-02 2025-04-10 イミュニティーバイオ インコーポレイテッド Pancreatic cancer treatment methods

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
WO2003104425A2 (en) 2003-12-18
WO2003104425A3 (en) 2005-02-17
AU2003239197A1 (en) 2003-12-22

Similar Documents

Publication Publication Date Title
EP1494693A4 (en) Cripto-specific antibodies
PL375405A1 (en) Antibodies
AU2003239197A8 (en) Novel stable anti-cd22 antibodies
EP1616881A4 (en) Anti-mpl antibodies
PT1599504E (en) Modified antibody
IL166084A0 (en) Novel benzodioxoles
PL371678A1 (en) Novel pyridin- and pyrimidin-derivatives
PL373598A1 (en) Novel benzonaphthyridines
GB0323336D0 (en) No Title
GB0316148D0 (en) No title
GB0426043D0 (en) Antibodies
GB0313380D0 (en) No Title
IL163529A0 (en) Novel spinosyn-producing polyketidesynthases
GB0321790D0 (en) No Title
GB0316267D0 (en) No Title
GB0314518D0 (en) No title
GB0306618D0 (en) Antibody
GB0306867D0 (en) No Title
GB0226878D0 (en) Antibodies
GB0317355D0 (en) No Title
GB0229743D0 (en) Novel benzoxazocines
GB0218234D0 (en) Antibodies
GB0203018D0 (en) Antibodies
GB0218232D0 (en) Antibodies
GB0218230D0 (en) Antibodies

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase